UBS AM
FLNA

UBS AM’s Filana Therapeutics FLNA Stock Holding History

UBS AM’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,424
Closed -$26.1K – 2706
2025
Q1 		$26.1K Sell
17,424
-57,660
-77% -$146K ﹤0.01% 2623
2024
Q4 		$177K Buy
75,084
+14,190
+23% +$249K ﹤0.01% 2636
2024
Q3 		$1.79M Sell
60,894
-13,075
-18% -$301K ﹤0.01% 2090
2024
Q2 		$914K Buy
73,969
+27,689
+60% +$584K ﹤0.01% 2422
2024
Q1 		$939K Hold
46,280
– – ﹤0.01% 2040
2023
Q4 		$1.04M Hold
46,280
– – ﹤0.01% 2003
2023
Q3 		$770K Hold
46,280
– – ﹤0.01% 2099
2023
Q2 		$1.12M Hold
46,280
– – ﹤0.01% 1954
2023
Q1 		$1.12M Buy
46,280
+14,542
+46% +$403K ﹤0.01% 1954
2022
Q4 		$938K Buy
31,738
+2,990
+10% +$107K ﹤0.01% 1877
2022
Q3 		$1.2M Sell
28,748
-3,778
-12% -$102K ﹤0.01% 1862
2022
Q2 		$915K Buy
32,526
+417
+1% +$10.5K ﹤0.01% 2013
2022
Q1 		$1.19M Buy
32,109
+5,727
+22% +$243K ﹤0.01% 2038
2021
Q4 		$1.15M Sell
26,382
-4,893
-16% -$257K ﹤0.01% 2139
2021
Q3 		$1.94M Sell
31,275
-201
-0.6% -$16.8K ﹤0.01% 1852
2021
Q2 		$2.69M Buy
+31,476
New +$1.69M ﹤0.01% 1725

Other funds holding FLNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

UBS AM's FLNA Position: Q2 2025 in Review

UBS AM sold out of Filana Therapeutics (FLNA) in Q2 2025, closing a stake of 17,424 shares — an estimated $26.1K sold.

UBS AM first reported a position in FLNA in Q2 2021 and held it in 16 quarters. The position peaked at $2.69M in Q2 2021. 97 funds tracked by Wall St. Rank hold FLNA as of Q2 2025.

  • UBS AM reported no remaining Filana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • UBS AM sold 17,424 Filana Therapeutics shares in Q2 2025, an estimated $26.1K.
  • UBS AM first reported a position in Filana Therapeutics in Q2 2021 and held it in 16 quarters.
  • UBS AM's Filana Therapeutics position peaked at $2.69M in Q2 2021.
  • 97 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2025.

Based on UBS AM's 13F filing for Q2 2025, filed 14 Aug 2025.